Sen. demands probe of early access to trial data

A weekend report in the Seattle Times that medical researchers are accepting large fees to deliver early news on the outcomes of clinical research trials has touched off a furor in Washington, DC. Senator Charles Grassley (R-Iowa), who has headed Senate probes of the pharmaceutical industry, has called for a formal investigation of 26 reported cases where early data on research trials were delivered to Wall Street research firms.

According to the report, Gerson Lehrman Group has 60,000 doctors available to discuss research information with clients who pay as much as $1 million per year for the information. But the research group denies any wrongdoing, saying that doctors are paid upwards of $500 per hour even if they cut off discussions when it involves confidential information.

- read this story from the San Francisco Chronicle

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.